Immunis Chairman Dr. Hans Keirstead to Present at the 2023 Biotech Showcase
Immunis Recruits Individuals with Muscle Atrophy for Phase 1/2a Clinical Trial
IRVINE, Calif. — January 16, 2023 — Immunis Inc.
was featured by DelveInsight Business Research LLP
as one of six companies with recent developments in researching a treatment for knee osteoarthritis. DelveInsight is a leading Business Consultant and Market Research Firm that examines the innovative landscape of the healthcare industry to inform decision-makers on critical issues and opportunities.
For more information about the article, read here